Skip to content

Indocyanine Green-Guided Omental Shield Anastomosis (ICG-OSA) for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy: A Single-Center, Single-Arm, Open-Label Clinical Study

Indocyanine Green-Guided Omental Shield Anastomosis (ICG-OSA) for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy: A Single-Center, Single-Arm, Open-Label Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116084
Enrollment
Unknown
Registered
2026-01-05
Start date
2026-01-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

Indocyanine Green-Guided Omental Shield Anastomosis (ICG-OSA) Intervention Group:Indocyanine Green-Guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis

Sponsors

Army Medical Center, Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1: Age 18 to 80 years, of both sexes; 2: Pathological diagnosis: Histologically confirmed esophageal squamous cell carcinoma (ESCC) by biopsy; 3: Clinical staging: Preoperative clinical stage cT1-4aN0-3M0 (according to the 8th edition AJCC staging criteria), evaluated by the thoracic surgery team as eligible for radical McKeown esophagectomy; 4: Performance status ECOG 0-1; 5: Major organ function (cardiovascular, respiratory, digestive, hematological systems) assessed as having no contraindications for chemotherapy or immunotherapy, and no surgical contraindications; 6: Able to understand and comply with study protocol requirements, and willing to accept and undergo standardized postoperative follow-up; 7: Able to understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1:   Allergy history: History of allergy to indocyanine green (ICG), iodide, or iodinated contrast agents (ICG contains iodine, and allergy may cause severe anaphylactic reactions); 2:   Severe hepatic or renal dysfunction: Severe hepatic insufficiency (Child-Pugh Class C) or severe renal insufficiency (eGFR <30 mL/min/1.73 m^2), affecting ICG metabolism and excretion; 3:   Unfavorable tumor location: Tumor located in the cervical or upper thoracic esophagus (<25 cm from the incisors), making it difficult to ensure negative proximal resection margin; 4:   Previous surgery history: Prior history of esophageal, gastric, or mediastinal surgery resulting in altered anatomy or severe adhesions; 5:   Multiple primary cancers: Concurrent active malignant tumors in other sites (except cured basal cell carcinoma of the skin or cervical carcinoma in situ); 6:   Special physiological status: Pregnant or lactating women, or those with planned pregnancy during the study period who are unwilling to use effective contraception; 7:   Cognitive and behavioral issues: Presence of severe psychiatric illness, cognitive impairment, or history of substance abuse that would preclude compliance with study procedures; 8:   Participation in other studies: Currently enrolled in other interventional clinical trials that may interfere with the results of this study; 9:   Investigator judgment: Investigator considers the patient unsuitable for this clinical study (e.g., intraoperative exploration reveals severe tumor invasion of major structures such as the aorta or trachea, making R0 resection unachievable).

Design outcomes

Primary

MeasureTime frame
Anastomotic Leakage Rate within 30 Days Postoperatively;

Secondary

MeasureTime frame
Subclinical Anastomotic Leakage Rate;Anastomotic Leakage-Related Complication Rate;Technique-Related Adverse Events;Health Economic Indicators;

Countries

China

Contacts

Public ContactWei Guo

Army Medical Center, Army Medical University

576875034@qq.com+86 23 6872 9280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026